STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-61)	IANALUMAB
PRONUNCIATION	eye” an al' ue mab
THERAPEUTIC CLAIM	Treatment of autoimmune diseases and cancer immunotherapy

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human cytokine receptor BAFF-R)(human monoclonalclone NVS230512 γ1-chain), disulfide with human monoclonal clone NVS230512 κ-chain, dimer (Source: CAS)

2. immunoglobulin G1-kappa, anti-[*Homo sapiens* TNFRSF13C (tumor necrosis factor receptor (TNFR) superfamily member 13C, BAFFR, BAFF-R, BR3, B cell activating factor receptor, CD268)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-454) [*Homo sapiens* VH (IGHV6-1*01 (96.00%) -(IGHD) -IGHJ5*01) [10.9.14] (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1 (CH1 R120 (221) (125-222), hinge (223-237), CH2 (238-347), CH3 E12 (363), M14 (365) (348-452), CHS (453-454)) (125-454)], (227-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3D-11*02 (89.00%) -IGKJ1*01) [7.3.9] (1'-108') -*Homo sapiens* IGKC*01, Km3 A45.1 (154), V101 (192) (109'-215')]; dimer (233-233'':236-236'')-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, glycoform alfa (Source: WHO pINN list 123)

STRUCTURAL FORMULA

Heavy chain

QVQLQQSGPG	LVKPSQTLSL	TCAISGDSVS	SNSAAWGWIR	QSPGRGLEWL	50
GRIYYRSKWY	NSYAVSVKSR	ITINPDTSKN	QFSLQLNSVT	PEDTAVYYCA	100
RYDWVPKIGV	FDSWGQGTLV	TVSSASTKGP	SVFPLAPSSK	STSGGTAALG	150
CLVKDYFPEP	VTVSWNSGAL	TSGVHTFPAV	LQSSGLYSLS	SVVTVPSSSL	200
GTQTYICNVN	HKPSNTKVDK	RVEPKSCDKT	HTCPPCPAPE	LLGGPSVFLF	250
PPKPKDTLMI	SRTPEVTCVV	VDVSHEDPEV	KFNWYVDGVE	VHNAKTKPRE	300
EQYNSTYRVV	SVLTVLHQDW	LNGKEYKCKV	SNKALPAPIE	KTISKAKGQP	350
REPQVYTLPP	SREEMTKNQV	SLTCLVKGFY	PSDIAVEWES	NGQPENNYKT	400
TPPVLDSDGS	FFLYSKLTVD	KSRWQQGNVF	SCSVMHEALH	NHYTQKSLSL	450
SPGK					454

Light chain

DIVLTQSPAT	LSLSPGERAT	LSCRASQFIS	SSYLSWYQQK	PGQAPRLLIY	50’
GSSSRATGVP	ARFSGSGSGT	DFTLTISSLE	PEDFAVYYCQ	QLYSSPMTFG	100’
QGTKVEIKRT	VAAPSVFIFP	PSDEQLKSGT	ASVVCLLNNF	YPREAKVQWK	150’
VDNALQSGNS	QESVTEQDSK	DSTYSLSSTL	TLSKADYEKH	KVYACEVTHQ	200’
GLSSPVTKSF	NRGEC				215’

Disulfide bridges

22-99	22’’-99’’	23’-89’	23’’’-89’’’	135’-195’	135’’’-195’’’	151-207	151’’-207’’
227-215’	227’’-215’’’	233-233’’	236-236’’	268-328	268’’-328’’	374-432	374’’-432’’

Glycosylation sites (N)

304	304’’

MOLECULAR FORMULA	$C_{6606}H_{10224}N_{1740}O_{2098}S_{40}$
MOLECULAR WEIGHT	148.9 kDa
TRADEMARK	None as yet
SPONSOR	Novartis Pharma AG
CODE DESIGNATIONS	NVP-VAY736, VAY736
CAS REGISTRY NUMBER	1929549-92-7
UNII	ZN2GQ3II96
WHO NUMBER	10580

gbk